Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

522 Postmarket Surveillance Studies Database
  • Print
  • Share
  • E-mail
-
The FDA has the authority to require device manufacturers to perform postmarket surveillance under Section 522 of the Food, Drugs and Cosmetics (FD&C) Act, when questions are identified for devices that meet the statutory criteria. This database contains information about 522 Postmarket Surveillance Studies that have been required. This database allows you to search information about the postmarket surveillance requirements by manufacturer or device.

Learn more...

            
  To search for Manufacturer beginning with a specific letter, select that letter
 
 A 
 B 
 C 
 D 
 E 
 F 
 G 
 H 
 I 
 J 
 L 
 M 
 N 
 O 
 P 
 R 
 S 
 T 
 U 
 V 
 W 
 X 
 Z 
 
 
   

Postmarket Surveillance Study


 
Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Delayed
522 Number / Requirement Number PS200005 / PSS001
Date Original Plan Accepted 06/05/2020
Date Current Plan Accepted 03/13/2023
Study Name Postmarket Surveillance Study
Device Name Desara One Single Incision Sling System
Root Document Number K191416 
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group Concurrent Control
Analysis Type Analytical
Study Population Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Objectives Prospective, Non-Randomized, Parallel Cohort, Multi-center Study of Desara One single incision sling compared to Desara Blue Sling System implanted via TOR for the treatment of women with stress urinary incontinence (SUI).
Study Population The device group is comprised of women with SUI treated with the Desara One sling.
The comparison group is comprised of women with SUI treated with the Desara Blue sling. The study inclusion/exclusion criteria are the same as for the device group
Sample Size At least 300 subjects overall (150 per arm) accounting for 25% attrition at 3 years will provide sufficient power for testing both safety endpoints (adverse event rates and revision/resurgery rate) using a +10% non-inferiority margin with 80% power and a one-sided 5% significance level. Expected AE rate for sling systems is 10%. Expected revision/resurgery rate for sling systems is 3.5%.
A sample size of 142 subjects overall (71 per arm), and accounting for 25% attrition at 3 years will provide sufficient power for testing the primary effectiveness endpoint with 80% power, a one-sided 5% significance level, and a 15% non-inferiority margin. Expected success rate for the sling systems is 85%.
Key Study Endpoints All study data will be collected on standardized electronic case report forms (eCRFs) provided by Caldera.
Follow-up Visits and Length of Follow-up 36 months
Hospital discharge, 2 weeks, 6 weeks, 6, 12, 24, and 36 months post procedure


Postmarket Surveillance Study Reporting Schedule

Reporting Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
6 month report 12/05/2020 12/07/2020 On Time
1 year report 06/05/2021 06/07/2021 On Time
18 month report 12/05/2021 12/08/2021 Overdue/Received
2 year report 06/05/2022 06/07/2022 Overdue/Received
30 month report 12/05/2022 12/06/2022 On Time
3 year report 06/05/2023 06/02/2023 On Time
42 month report 12/05/2023 12/05/2023 On Time
4 year report 06/05/2024 06/05/2024 On Time
54 month report 12/05/2024   Overdue
5 year report 06/05/2025    


Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources
-
-